恶性肿瘤患者尿液β_2－m、Alb和IgGRlA联合检测的临床价值  

Role of Radioimmunologic Assay of Urine β_2-m, Albumin and IgG in Cancer Patients

作　　者：梅昆[1] 李静[1] 

机构地区：[1]青岛市肿瘤医院,青岛市肿瘤医院核医学科,青岛市肿瘤医院内科

出　　处：《中国肿瘤临床》1995年第3期187-190,共4页Chinese Journal of Clinical Oncology

摘　　要：报告６３３例恶性肿瘤患者和４０名正常人的尿液β２－ｍ、Ａｌｂ和ＩｇＧ的放射免疫检测结果。其中，３８９例恶性肿瘤患者的尿β２－ｍ测定值、４０７例患者的尿Ａｌｂ测定值和４１６例患者的尿ＩｇＧ测定值明显高于正常对照组（Ｐ＜０．００１）。作者认为，联合检测恶性肿瘤患者尿液β２－ｍ、Ａｌｂ，ＩｇＧ含量，在排除了肾脏疾病和自身免疫性疾病情况下，可作为恶性肿瘤有价值的辅助诊断指标和观察肿瘤病人肾功能变化的可靠而灵敏的指标。The β2-m,albumin and IgG levels in urine from 633 cancer patients were measured with RIA.It was shown that of the 633 cancer patients,urine β2-m level in 389 patients and albumin level in 407 patients and IgG level in 416 patients were significantly higher than those in healthy porous. Our data suggest that urine β2-m,albumin and IgG levels measurement are valuable in cancer diagnosis and are sensitive parameters in observing renal function of cancer patients,provided other renal diseases and autoimmune disease can be excluded.

关 键 词：Β2微球蛋白 免疫球蛋白G 恶性肿瘤 清蛋白 

分 类 号：R730.43[医药卫生—肿瘤]